Agostino Tafuri

Publications

Title Published on Year
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomised trial BLOOD ADVANCES 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2024
Low Cell Bioenergetic Metabolism Characterizes Chronic Lymphocytic Leukemia Patients with Unfavorable Genetic Factors and with a Better Response to BTK Inhibition CURRENT ISSUES IN MOLECULAR BIOLOGY 2024
BASELINE QUALITY OF LIFE DATA MAY PREDICT ACHIEVEMENT OF EMR IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TKIS: RESULTS FROM THE GIMEMA-SUSTRENIM TRIAL HEMASPHERE 2024
HYPEREOSINOPHILIC DISORDERS: PRELIMINARY REAL-WORLD ANALYSIS BY PH-NEGATIVE MPN LATIAL GROUP HEMASPHERE 2024
A Rare Case of Primary Bone Follicular Lymphoma with Multiple Osteolytic Lesions: A Case Report and Review of the Literature HEMATO 2024
CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience HEMASPHERE 2024
Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study JOURNAL OF CLINICAL MEDICINE 2023
Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin's disease FRONTIERS IN ONCOLOGY 2023
YY1 knockdown relieves the differentiation block and restores apoptosis in AML cells CANCERS 2023
Doxorubicin-Induced Cardiac Senescence Is Alleviated Following Treatment with Combined Polyphenols and Micronutrients through Enhancement in Mitophagy CELLS 2023
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas HEMATOLOGICAL ONCOLOGY 2023
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi HEMATOLOGICAL ONCOLOGY 2023
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial BLOOD 2023
The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features BRITISH JOURNAL OF HAEMATOLOGY 2023
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study LEUKEMIA 2023
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study FRONTIERS IN PHARMACOLOGY 2023
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL) HAEMATOLOGICA 2023
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling BRITISH JOURNAL OF HAEMATOLOGY 2023
Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 7162 JOURNAL OF CLINICAL MEDICINE 2023

ERC

  • LS1_9
  • LS2_15
  • LS3_1
  • LS3_5
  • LS4_11

KET

  • Life-science technologies & biotechnologies

Interessi di ricerca

Keywords

Acute leukemia
molecular targeted therapies
drug resistance
cell signaling
cell metabolism

Progetti di Ricerca

Laboratori di ricerca

Laboratorio di cinetica cellulare, signaling e metabolismo in ematologia

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma